Tawatchai Suwanban
Overview
Explore the profile of Tawatchai Suwanban including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iam-Arunthai K, Chamnanchanunt S, Thungthong P, Chinapha A, Nakhahes C, Suwanban T, et al.
Front Med (Lausanne)
. 2024 May;
11:1346646.
PMID: 38711780
Objective: This study aimed to evaluate the relationship between high-sensitivity C-reactive protein (hsCRP) in hospitalized COVID-19 patients and their clinical outcomes, including trajectory of hsCRP changes during hospitalization. Method And...
2.
Iam-Arunthai K, Chamnanchanunt S, Thungthong P, Intalapaporn P, Nakhahes C, Suwanban T, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592277
Internationally established guidelines mention pharmacological prophylaxis for all hospitalized COVID-19 patients. However, there are concerns regarding the efficacy and safety of anticoagulants. This study investigated the associations between thrombosis/bleeding risk...
3.
Thanhakun R, Wudhikarn K, Bunworasate U, Rattanathammethee T, Norasetthada L, Kanya P, et al.
Ann Hematol
. 2023 Sep;
102(12):3533-3541.
PMID: 37718327
Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which...
4.
Atypical complication in an adult patient with dengue and autoimmune hemolytic anemia: a case report
Chamnanchanunt S, Thungthong P, Nakhakes C, Chonsawat P, Suwanban T
Asian Biomed (Res Rev News)
. 2023 Aug;
15(1):43-48.
PMID: 37551296
Severe dengue infection is associated with life-threatening complications, including severe bleeding. The bleeding tendency is typically associated with the shock phase of infection, for which blood replacement may be needed....
5.
Suwanban T, Chamnanchanunt S, Thungthong P, Nakhahes C, Iam-Arunthai K, Akrawikrai T, et al.
Cancer Rep (Hoboken)
. 2023 May;
6(8):e1839.
PMID: 37254799
Background: The survival rate of adult patients with Hodgkin lymphoma (HL) depends on the responses to standard chemotherapy, radiotherapy, or combined therapy. Resource-limited countries face numerous obstacles in supporting patients...
6.
Rattanathammethee T, Norasetthada L, Bunworasate U, Wudhikarn K, Julamanee J, Noiperm P, et al.
Ann Hematol
. 2023 May;
102(7):1887-1895.
PMID: 37202499
Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is a challenging condition to treat, and there is an unmet clinical need for effective therapies. Recently, polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate...
7.
Thungthong P, Chamnanchanunt S, Suwanban T, Nakhahes C, Iam-Arunthai K, Akrawikrai T, et al.
Front Med (Lausanne)
. 2023 Mar;
10:1122282.
PMID: 36993799
Background: A tool for estimating risk of febrile neutropenia (FN) after chemotherapy, namely the FEbrile Neutropenia after ChEmotherapy (FENCE) score, has been developed but has not been widely validated. This...
8.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
Leuk Lymphoma
. 2020 Jun;
61(11):2614-2621.
PMID: 32573294
Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 in advanced-stage...
9.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
Hematol Oncol
. 2019 Nov;
37(5):578-585.
PMID: 31702065
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T...
10.
Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, et al.
J Geriatr Oncol
. 2019 Apr;
11(1):62-68.
PMID: 30940492
Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups....